申请人:Portola Pharmaceuticals, Inc.
公开号:EP1734041A2
公开(公告)日:2006-12-20
Novel compound of formulae (I), which more particularly, include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to the use of an effective amount of a compound of formulae (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for preventing or treating thrombosis in a mammal.
式(I)的新型化合物,尤其包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰基胍衍生物、硫酰基磺酰胺衍生物和酰基磺酰胺衍生物,它们是有效的血小板 ADP 受体抑制剂。这些衍生物可用于各种药物组合物中,对预防和/或治疗心血管疾病,尤其是与血栓形成有关的疾病特别有效。本发明还涉及将有效量的式(I)化合物或其药学上可接受的盐用于制造预防或治疗哺乳动物血栓形成的药物组合物。